Le Lézard
Classified in: Health, Science and technology, Business
Subjects: PDT, LIC

Accure Acne and Quanta System Announce Commercial Partnership in the EU to Broaden Adoption of The Accure Laser


Access to Quanta System's Distribution Network Will Allow EU Clinicians to Acquire the Groundbreaking Accure Laser System

BOULDER, Colo., June 13, 2024 /PRNewswire/ -- Accure Acne, Inc.tm (www.accureacne.com), a pioneer in innovative acne treatment solutions, announced today that Accure and Quanta System will expand their successful partnership, enhancing access to the revolutionary Accure Laser System in Europe. Quanta will leverage its robust distribution platform to provide clinicians across the EU with this new acne treatment method.

Access to Quanta System's Distribution Network Will Allow EU Clinicians to Acquire the Groundbreaking Accure Laser

"Our partnership with Quanta has been foundational for Accure," commented Christopher Carlton, Co-Founder, Chairman, and CEO of Accure Acne, Inc. "Expanding this relationship to accelerate our access to the EU marketplace is exciting. Quanta's commercial expertise and success history should yield significant impact this year."

The Accure Laser System employs the 1726 nm laser wavelength with proprietary technology to control thermal gradient depth, maximizing impact on the sebaceous gland. This AcneTech breakthrough includes a unique pulsing algorithm, integrated temperature monitoring, and precise automated control. During a limited commercial release, several European providers have reported compelling clinical outcomes. The Accure Laser achieved the first-ever CE 0123 Mark certification for a 1726nm-based device for treatment of mild to moderate inflammatory acne vulgaris and has received FDA clearance for treatment of mild to severe inflammatory acne vulgaris.

"I have used the Accure Laser for over a year with excellent, consistent results," added Christine Dierickx, MD, Founder of Skinperium Cosmetic Dermatology in Luxembourg. "Patients are seeking non-systemic acne treatments with strong outcomes. I'm pleased to see Accure and Quanta expand access to this device in Europe."

"The Accure Laser offers an exciting opportunity for our commercial partners," said Girolamo Lionetti, CEO of Quanta System. "We've partnered with Accure from the beginning and are proud to enhance our mission to bring revolutionary technology to clinicians, impacting patients' lives."

About Accure Acne, Inc.

Accure Acne, Inc. is dedicated to developing revolutionary solutions for eliminating acne, addressing its social, psychological, physical, and economic impacts. We pioneer transformative solutions to meet this unmet need, positively impacting patients and providers worldwide. Learn more: www.accureacne.com

Contact: Haigo Manukian ? [email protected]

About Quanta System SpA

Quanta System SpA, an Italian company, has been a leader in laser systems for surgery, dermatology, aesthetic medicine, and art conservation for nearly 40 years. Part of El.En. SpA, Quanta innovates to meet professionals' needs, enhancing patient care globally.

Contact: Carolina Crepaldi[email protected]

SOURCE Accure Acne, Inc.


These press releases may also interest you

at 12:07
The Women in Insurance Cancer Crusade (WICC) took another step closer to its goal of raising $25 million by 2025 at their annual Relay for Life fundraising event, held on June 6th . Nearly 300 people came together for an evening of camaraderie for...

at 12:00
"I wanted to create a simple and attractive way to secure your glasses to your shirt, jacket or other article of clothing," said an inventor, from Port St. Lucie, Fla., "so I invented the EYEGLASS PIN HOLDER. My design enables you to keep your...

at 11:56
Northwest Biotherapeutics ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on June 29, 2024. ...

at 11:32
The American Parkinson Disease Association (APDA) is celebrating the President's signing of the National Plan to End Parkinson's Act yesterday, marking the enactment of the first-ever federal legislation dedicated to curing and preventing Parkinson's...

at 11:30
NeuroCytonix, Inc., today announced that on May 27, 2024, its subsidiary NeuroCytonix Mexico received a regulatory approval letter from the ethical, scientific, and safety committees of Hospital La Mision in Monterrey, Mexico, to launch a clinical...

at 11:00
States with high rates of COVID-19 vaccination saw more pediatric asthma patients get a break from their symptoms, according to new research published today in JAMA Network Open by leaders from Nemours Children's Health and Endeavor Health....



News published on and distributed by: